Use of Gemcitabine, Cisplatin and Methylprednisolone (GEM-P) with or without Rituximab in Relapsed and Refractory Patients with Diffuse Large B Cell Lymphoma (DLBCL).

MLA

Sirohi, Bhawna, et al. “Use of Gemcitabine, Cisplatin and Methylprednisolone (GEM-P) with or without Rituximab in Relapsed and Refractory Patients with Diffuse Large B Cell Lymphoma (DLBCL).” Blood, vol. 106, no. 11, Nov. 2005, p. 939. EBSCOhost, https://doi.org/10.1182/blood.V106.11.939.939.

APA

Sirohi, B., Cunningham, D., Norman, A., Trumper, M., Rao, S., Murray, T., Prior, Y., Chong, G., Last, K., & Wotherspoon, A. (2005). Use of Gemcitabine, Cisplatin and Methylprednisolone (GEM-P) with or without Rituximab in Relapsed and Refractory Patients with Diffuse Large B Cell Lymphoma (DLBCL). Blood, 106(11), 939. https://doi.org/10.1182/blood.V106.11.939.939

Chicago

Sirohi, Bhawna, David Cunningham, Andy Norman, Michele Trumper, Sheela Rao, Tracey Murray, Yvonne Prior, Geoffrey Chong, Kim Last, and Andrew Wotherspoon. 2005. “Use of Gemcitabine, Cisplatin and Methylprednisolone (GEM-P) with or without Rituximab in Relapsed and Refractory Patients with Diffuse Large B Cell Lymphoma (DLBCL).” Blood 106 (11): 939. doi:10.1182/blood.V106.11.939.939.